C9orf72 and amyotrophic lateral sclerosis: Although previous trials of ASO therapies for C9orf72 expansions were terminated due to lack of efficacy, exploration of other genetically-targeted drug treatments for C9orf72 expansions are ongoing and an urgent priority for the MND/ALS community.